Shionogi to acquire US biotech for $2 billion

The story

Shionogi & Co., Ltd. announced plans to acquire US biopharmaceutical company IntraBio through its US group company and make it a wholly owned subsidiary. The total transaction value is reported to be $2 billion.

IntraBio has an NPC treatment approved in the United States and Europe, and the acquisition is expected to expand Shionogi & Co., Ltd.'s treatment portfolio.

At a glance

Acquisition targetIntraBio is expected to be acquired and made a wholly owned subsidiary.

Amount (USD)The transaction has been announced as a $2 billion cash deal.

Transaction typeThe acquisition is expected to be carried out through the creation of a wholly owned subsidiary.

Business AreasThe related business, which has an NPC treatment, will be integrated.

Reference information. Every claim resolves to something the story actually named.

Where this came from

We read each source in full and checked they agree on the core claim.

1/ 1 agree

All of them report the same thing.

nk.jiho.jpNews

AgreesOpen

Read the original articleGo to the source page

Reference information generated from public sources. It does not solicit or advise on investments. Prices are 15-minute delayed.